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As Friedrich Hegel stated, “The only thing 
we learn from history is that we learn noth-
ing from history.” In my career of more than 
25 years in the pharmaceutical industry, I 
continue to witness the same lack of plan-
ning, systematic sloppiness, and missteps 
that I saw at the beginning of my career in 
determining risk during the pre-marketing 
phase of a drug’s lifecycle.
Determining risk during this period 
is inherently challenging due to limited 
exposure to an investigational drug. 
The recommended minimum size of 
the safety database for long-term use 
for non-threatening conditions is 1500 
patients with 300–600 patients exposed 
to the investigational drug for at least 
6 months and 100 patients exposed for 
at least 1 year (ICH Secretariat, 1994). 
This means that based on the “Rule of 3,” 
if 1500 patients were given an investiga-
tional drug and an adverse reaction, for 
example hepatotoxicity, was not seen, one 
can be 95% confident that the true inci-
dence of hepatotoxicity is less than 0.2% 
(1500/3 = 500; 1/500 = 0.2%; Rosner, 1995; 
US Department of Health and Human 
Services, Food and Drug Administration, 
Center for Drug Evaluation and Research, 
Center for Biologics Evaluation and 
Research, 2009). With these known limita-
tions there are many proactive approaches 
that can be taken that will enhance risk 
assessment throughout the clinical devel-
opment phase of a drug’s lifecycle. To do 
this it is helpful to “begin at the end.” The 
“end” is the manufacturer must show 
a favorable benefit–risk profile before 
market authorization (drug approval) is 
granted. To do this, because of the lim-
ited exposure to the investigational drug, 
safety data will in most cases have to be 
pooled (combined) across clinical studies 
in order to enhance the ability to identify 
and characterize the drug’s risk profile. 
Many manufacturers do this data pool-
ing (integration) at the end of a clinical 
development program, where in reality 
it should be done at the beginning of the 
clinical development program.
There are many steps required to take 
the safety data collected from a clinical 
study site, i.e., raw data, and convert it into 
data that allows aggregate analyses, i.e., 
analyses of data from groups of patients, 
so changes from baseline (pre-treatment) 
values and comparisons of these changes 
from baseline can be compared between 
treatment groups (e.g., the investigational 
group vs. the placebo group) in order to 
identify any differences. Any identified 
differences between treatment groups can 
indicate a drug effect. These various steps 
include: data entry; coding of adverse 
event (AE) data, e.g., to ensure standard 
medical terms are used for similar medi-
cal concepts [e.g., the use of the Medical 
Dictionary for Regulatory Activities 
(MedDRA) so an accurate incidence of 
AEs can be determined]; data program-
ming and data analysis with the creation 
of tables, listings, and figures (TLFs); and 
summarizing and interpreting the ana-
lyzed data so that a risk assessment can be 
done (Medical Dictionary for Regulatory 
Activities, 2010). Any misstep along this 
data pathway can result in an incorrect 
assessment of risk. Some of the common 
problems encountered include: collecting 
incorrect information; missing informa-
tion; delays in data entry; data entry errors; 
programming errors; doing the wrong 
types of analyses; and errors in data inter-
pretation. Many of these problems are not 
identified at the individual study level but 
become more evident when the data are 
pooled. Programming and data analy-
ses also become more complicated when 
more studies are combined together. All of 
these potential problems can be minimized 
by good planning, ongoing review of the 
data, correcting data errors, and obtain-
ing missing information in “real time.” It 
is also important to have a close collabora-
tion between the medical writer, medical 
reviewer, programmer, and statistician to 
ensure any errors in programming or data 
analyses are identified early and corrected. 
This is all accomplished by creating and 
maintaining a “dynamic” integrated safety 
database early on in the clinical develop-
ment program rather than doing this at 
the time of the preparation of the sum-
mary of clinical safety (SCS) and/or inte-
grated summary of safety (ISS). The SCS 
and ISS are documents that are required 
for submission in order to obtain market 
authorization in the European Union and 
the United States (ICH Secretariat, 2002; 
US Department of Health and Human 
Services, Food and Drug Administration, 
Center for Drug Evaluation and Research, 
Center for Biologics Evaluation and 
Research, 1988). The word “dynamic” is 
used to convey that the database will not 
be static but will change and grow with 
the completion of each study. When data 
are displayed in TLFs, it is easier to iden-
tify missing information and errors such 
as data or programming errors early on. 
Fixing errors and obtaining missing infor-
mation improves the quality of the data. 
Pooled data with more and more studies 
added to the database also increases the 
chances of identifying new safety signals 
sooner than later. The building blocks of 
the integrated database are the raw data 
referred to as data elements, and the sta-
tistical analysis plan (SAP) is the blue print 
of how the database will be built. The 
SAP defines how the data will be pooled, 
counted, analyzed, and displayed. The 
majority of safety analyses are analyzed the 
same way across studies as well as for dif-
ferent development programs evaluating 
different investigational drugs. Therefore 
in many cases a SAP created for one inves-
tigational drug can be recycled and used 
for other investigational drugs. Elements 
of the SAP for the integrated database can 
also be used for preparation of individual 
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clinical study reports. Another benefit is 
that early integration forces standardiza-
tion of the data that is a requirement for 
data pooling. For example, if reasons for 
premature termination of treatment are 
not standardized, and different reasons 
are used across studies, e.g., one study has 
five reasons, another study has seven rea-
sons, while another study might have six 
reasons, a standard category for reasons 
for discontinuation will have to be estab-
lished for the SCS/ISS so this information 
can be pooled across studies. In order to do 
this the studies using different reasons for 
discontinuation will have to be mapped to 
the standard categories established for the 
SCS/ISS. Using standard data at the begin-
ning of the clinical development program 
will obviate the need for data mapping. By 
doing this, transcription errors are avoided 
and time, money, and resources are saved. 
For all these reasons, the most important 
being enhanced ability to detect safety 
signals and better data quality, the crea-
tion, and maintenance of a “dynamic” inte-
grated database, is highly recommended.
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